Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage non-small cell lung cancer.

R. Brian Mitchell; Patricia Rich; Paul R. Walker; Eric S Schaefer; Jiahuai Tan; Nagaprasad Nagajothi; John W. Dubay; Jason Keith Boyd; David N. Oubre; Nadeem Ikhlaque; Ray D. Page; Mazen Khalil; Suman Sinha; Hafez Halawani; S. Scott Boniol; Edgardo S. Santos; James Michael Orsini; Emily K. Pauli; Wallace L. Akerley; Insight Investigators

doi:10.1200/JCO.2020.38.15_SUPPL.9545

Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage non-small cell lung cancer.

R. Brian Mitchell
, Patricia Rich
, Paul R. Walker
, Eric S Schaefer
, Jiahuai Tan
, Nagaprasad Nagajothi
, John W. Dubay
, Jason Keith Boyd
, David N. Oubre
, Nadeem Ikhlaque
, Ray D. Page
, Mazen Khalil
, Suman Sinha
, Hafez Halawani
, S. Scott Boniol
, Edgardo S. Santos
, James Michael Orsini
, Emily K. Pauli
, Wallace L. Akerley
, Insight Investigators

Virginia Cancer Inst, Midlothian, VA;
Cancer Treatment Centers of America
East Carolina University
Highlands Oncology Group, Fayetteville, AR;
Wayne State University
Mercy Medical Cancer Center, Canton, OH;
Lewis & Faye Manderson Cancer Center at DCH Regional Medical Center, Tuscaloosa, AL;
Southeastern Med Oncology Center, Goldsboro, NC;
Pontchartrain Hem Oncol, Mandeville, LA;
Franciscan St. Francis, Indianapolis, IN;
The Center for Cancer and Blood Disorders, Fort Worth, TX;
Clopton Clinic, Jonesboro, AR;
Christus Health
Christus Cabrini Cancer Ctr, Alexandria, LA;
Christus Cancer Treatment Center, Kouns Shreveport, LA;
Lynn University
Newark Beth Israel Medcl Ctr, Newark, NJ;
Clearview Cancer Institute, Huntsville, AL;
Huntsman Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	38
DOIs	https://doi.org/10.1200/JCO.2020.38.15_SUPPL.9545
State	Published - May 25 2020
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1200/JCO.2020.38.15_SUPPL.9545License: Unspecified

Cite this

Mitchell, R. B., Rich, P., Walker, P. R., Schaefer, E. S., Tan, J., Nagajothi, N., Dubay, J. W., Boyd, J. K., Oubre, D. N., Ikhlaque, N., Page, R. D., Khalil, M., Sinha, S., Halawani, H., Boniol, S. S., Santos, E. S., Orsini, J. M., Pauli, E. K., Akerley, W. L., & Investigators, I. (2020). Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage non-small cell lung cancer. Journal of Clinical Oncology, 38. https://doi.org/10.1200/JCO.2020.38.15_SUPPL.9545

Mitchell, RB, Rich, P, Walker, PR, Schaefer, ES, Tan, J, Nagajothi, N, Dubay, JW, Boyd, JK, Oubre, DN, Ikhlaque, N, Page, RD, Khalil, M, Sinha, S, Halawani, H, Boniol, SS, Santos, ES, Orsini, JM, Pauli, EK, Akerley, WL & Investigators, I 2020, 'Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage non-small cell lung cancer.', Journal of Clinical Oncology, vol. 38. https://doi.org/10.1200/JCO.2020.38.15_SUPPL.9545

@article{328c6e4dad704d048e86400754d30666,

title = "Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage non-small cell lung cancer.",

author = "Mitchell, \{R. Brian\} and Patricia Rich and Walker, \{Paul R.\} and Schaefer, \{Eric S\} and Jiahuai Tan and Nagaprasad Nagajothi and Dubay, \{John W.\} and Boyd, \{Jason Keith\} and Oubre, \{David N.\} and Nadeem Ikhlaque and Page, \{Ray D.\} and Mazen Khalil and Suman Sinha and Hafez Halawani and Boniol, \{S. Scott\} and Santos, \{Edgardo S.\} and Orsini, \{James Michael\} and Pauli, \{Emily K.\} and Akerley, \{Wallace L.\} and Insight Investigators",

note = "9545 Background: Immune checkpoint inhibition (ICI) has improved outcomes for many treatment-na{\"i}ve advanced non-small cell lung cancer (NSCLC) patients. However, better biomarkers are needed to predict patient response and guide treatment decisions considering added toxicity and higher cost of combination treatments.",

year = "2020",

month = may,

day = "25",

doi = "10.1200/JCO.2020.38.15\_SUPPL.9545",

language = "American English",

volume = "38",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage non-small cell lung cancer.

AU - Mitchell, R. Brian

AU - Rich, Patricia

AU - Walker, Paul R.

AU - Schaefer, Eric S

AU - Tan, Jiahuai

AU - Nagajothi, Nagaprasad

AU - Dubay, John W.

AU - Boyd, Jason Keith

AU - Oubre, David N.

AU - Ikhlaque, Nadeem

AU - Page, Ray D.

AU - Khalil, Mazen

AU - Sinha, Suman

AU - Halawani, Hafez

AU - Boniol, S. Scott

AU - Santos, Edgardo S.

AU - Orsini, James Michael

AU - Pauli, Emily K.

AU - Akerley, Wallace L.

AU - Investigators, Insight

N1 - 9545 Background: Immune checkpoint inhibition (ICI) has improved outcomes for many treatment-naïve advanced non-small cell lung cancer (NSCLC) patients. However, better biomarkers are needed to predict patient response and guide treatment decisions considering added toxicity and higher cost of combination treatments.

PY - 2020/5/25

Y1 - 2020/5/25

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.9545

U2 - 10.1200/JCO.2020.38.15_SUPPL.9545

DO - 10.1200/JCO.2020.38.15_SUPPL.9545

M3 - Article

VL - 38

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage non-small cell lung cancer.

Disciplines

Access to Document

Other files and links

Cite this